Summit Therapeutics’ partner Akeso reported an incremental piece of good news for the pair’s closely-watched PD-1xVEGF bispecific antibody ivonescimab.
In a China-only study called HARMONi-A, ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit ...
↧